文献速递甲状腺疾病垂体与肾上腺疾病

多发性内分泌腺瘤病1型患者行甲状旁腺切除术时合并甲状腺癌的情况

Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism.
PubMed 文献 · Thyroid · 2019-01-01

本研究比较了因原发性甲状旁腺功能亢进而行甲状旁腺切除术的MEN1患者(MPHP)与散发性患者(SPHP)合并甲状腺癌的发生率和特征。结果显示MPHP组甲状腺癌发生率为28%,但均为常规乳头状癌,无临床显著(>1 cm)甲状腺癌;SPHP组临床显著甲状腺癌发生率为26%。MPHP组术前未计划甲状腺切除的比例更高(83% vs 34%)。

要点

  • MPHP患者甲状腺癌发生率为28%,但均为常规乳头状癌且无临床显著癌。
  • MPHP组术前未计划甲状腺切除比例显著高于SPHP组(83% vs 34%)。
  • MPHP并非甲状腺癌的独立危险因素(OR=1.14,p=0.83)。

核心结论

  • MEN1患者行甲状旁腺切除术时甲状腺癌发生率为28%,但临床显著甲状腺癌不常见。
  • MPHP患者术前未计划甲状腺切除的比例显著高于SPHP患者。

研究设计与样本

  • 前瞻性数据库回顾性分析,纳入1967至2014年行初次或再次甲状旁腺探查的MPHP患者29例和年龄性别匹配的SPHP患者58例。
  • MPHP诊断基于临床和/或遗传学标准。

主要发现

  • MPHP组甲状腺癌发生率为28%(8/29),SPHP组为47%(27/58),差异无统计学意义(p=0.11)。
  • MPHP组术前未计划甲状腺切除比例为83%(24/29),SPHP组为34%(20/58),p<0.01。
  • 在术前未计划甲状腺切除的患者中,MPHP组组织学甲状腺癌发生率为13%(3/24),SPHP组为25%(5/20),p=0.44。
  • MPHP组无临床显著甲状腺癌(>1 cm),SPHP组发生率为26%(15/58),p<0.01。
  • MPHP组甲状腺癌均为常规乳头状癌,SPHP组包括乳头状癌(66%)和滤泡变异型乳头状癌(34%)。

关键数值与推荐

  • 临床显著甲状腺癌定义为直径>1 cm。
  • 多因素分析显示MPHP与甲状腺癌无显著关联(OR=1.14,p=0.83)。

临床怎么用

  • MEN1患者行甲状旁腺切除术时发现甲状腺癌的几率较高,但多为常规乳头状癌且无临床显著癌。
  • 术前应充分评估甲状腺情况,避免不必要的甲状腺切除。

局限性

  • 回顾性研究,样本量较小(MPHP组29例)。
  • 甲状腺切除的指征和时间段存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Compared to those with sporadic primary hyperparathyroidism (SPHP), multiple endocrine neoplasia type 1 (MEN1) patients with primary hyperparathyroidism (MPHP) typically require more extensive dissection and have higher recurrence rates. Little is known about the risk of concomitant thyroid cancer in either setting. This study aimed to determine the rates and characteristics of thyroid cancer for MPHP versus SPHP patients undergoing parathyroidectomy. METHODS: Patients with MPHP (diagnosed by clinical and/or genetic criteria) or SPHP who had initial or reoperative parathyroid exploration from 1967 to 2014 were identified via a prospective database. The thyroid cancer-specific data for MPHP patients (n = 29) were compared to a selected 2:1 age- and sex-matched SPHP cohort (n = 58) who all had concurrent thyroidectomy for any reason. Clinically significant thyroid cancer was defined as >1 cm in diameter. RESULTS: In the MPHP group, 24/29 (83%) thyroidectomies were preoperatively unplanned versus 20/58 (34%) in the SPHP matched cohort (p < 0.01), and in this setting there was no difference in the rate of histologic thyroid cancer (3/24 [13%] vs. 5/20 [25%], p = 0.44). Histologic thyroid cancer was identified in 8/29 (28%) MPHP versus 27/58 (47%) SPHP patients (p = 0.11). Despite observed differences in the time period and extent of thyroidectomy, MPHP patients did not have an increased likelihood of thyroid cancer (surgery before 2005: odds ratio [OR] = 2.57, p = 0.09; total thyroidectomy: OR = 5.47, p < 0.01; MPHP: OR = 1.14, p = 0.83). All MPHP thyroid cancers were characterized as conventional papillary thyroid cancer (PTC), while thyroid cancers in SPHP patients included both PTC (66%) and follicular-variant PTC (34%). No MPHP patient had clinically significant thyroid cancer compared to an incidence of 15/58 (26%) in SPHP patients (p < 0.01). CONCLUSIONS: Although patients with MEN1 have a substantial incidence of thyroid cancer (28%) and undergo more unplanned thyroidectomies during parathyroidectomy than do patients with SPHP, clinically significant thyroid cancer is proportionally uncommon.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Hill KA, Yip L, Carty SE, et al. Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism. Thyroid. 2019. PMID: 30608029. doi:10.1089/thy.2017.0675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。